Market Cap 1.44B
Revenue (ttm) 10.59M
Net Income (ttm) -68.99M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -651.46%
Debt to Equity Ratio 0.00
Volume 923,200
Avg Vol 777,482
Day's Range N/A - N/A
Shares Out 60.09M
Stochastic %K 28%
Beta 2.82
Analysts Strong Sell
Price Target $78.38

Company Profile

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms technology to treat patients with cancer. Its clinical candidates include JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer and the vasculature of other tumors; and JANX008, a...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 751 4493
Address:
10955 Vista Sorrento Parkway, Suite 200, San Diego, United States
PinbarBeast
PinbarBeast Oct. 5 at 8:31 AM
$JANX Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
Optionking828
Optionking828 Oct. 3 at 2:17 PM
$JANX always something weird. Dave Campbell is most likely a scammer
1 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 9:20 AM
$JANX: Unusual Options Activity Alerted PUT flow observed 400x contracts at Strike price of $20 Exp on 11/21/2025 with Premium of $52K and showing BEARISH Sentiment
1 · Reply
Houseofsweeps
Houseofsweeps Oct. 1 at 2:09 PM
$JANX I bought more today let's ride 🤣
1 · Reply
TKkamen
TKkamen Oct. 1 at 1:47 PM
$JANX what’s the rumor?
0 · Reply
RonIsWrong
RonIsWrong Oct. 1 at 1:42 PM
$JANX alright, looking better
0 · Reply
CooperHandy
CooperHandy Sep. 30 at 2:35 PM
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 4:47 PM
$JANX: TRADE PUT trade alert 21 @ 12.10, Strike 35.0, Exp 11/21/2025, Premium $25,410, Sentiment BEARISH
0 · Reply
CH_Expat
CH_Expat Sep. 26 at 5:52 AM
$JANX Basically cash level. Even if the weird rumors are true, there is a lot of value in it. I keep watching.
3 · Reply
CH_Expat
CH_Expat Sep. 22 at 10:10 AM
$JANX For transparency, I sold. The weird rumour about 007 plus Robinson leaving plus the technicals are concerning me a bit.
2 · Reply
Latest News on JANX
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025

Jul 17, 2025, 4:30 PM EDT - 2 months ago

Janux Therapeutics to Host Virtual R&D Day on July 24, 2025


Best-Performing Stocks Of 2024

Jan 2, 2025, 11:46 PM EST - 9 months ago

Best-Performing Stocks Of 2024

APP BYRN CADL DAVE INOD LUNR MSTR


Janux Therapeutics Announces Proposed Public Offering

Dec 3, 2024, 4:01 PM EST - 10 months ago

Janux Therapeutics Announces Proposed Public Offering


Janux Therapeutics Announces Updates to Board of Directors

Jul 22, 2024, 4:01 PM EDT - 1 year ago

Janux Therapeutics Announces Updates to Board of Directors


Janux Therapeutics (JANX) stock has gone parabolic: what next?

Apr 30, 2024, 12:06 AM EDT - 1 year ago

Janux Therapeutics (JANX) stock has gone parabolic: what next?


Janux Therapeutics: A Prime Target In Cancer Care's M&A Game

Apr 11, 2024, 9:00 AM EDT - 1 year ago

Janux Therapeutics: A Prime Target In Cancer Care's M&A Game


PinbarBeast
PinbarBeast Oct. 5 at 8:31 AM
$JANX Biotech with novel approach. High short interest. Potential squeeze setup if data positive. High risk/reward.
0 · Reply
Optionking828
Optionking828 Oct. 3 at 2:17 PM
$JANX always something weird. Dave Campbell is most likely a scammer
1 · Reply
SweepCastApp
SweepCastApp Oct. 2 at 9:20 AM
$JANX: Unusual Options Activity Alerted PUT flow observed 400x contracts at Strike price of $20 Exp on 11/21/2025 with Premium of $52K and showing BEARISH Sentiment
1 · Reply
Houseofsweeps
Houseofsweeps Oct. 1 at 2:09 PM
$JANX I bought more today let's ride 🤣
1 · Reply
TKkamen
TKkamen Oct. 1 at 1:47 PM
$JANX what’s the rumor?
0 · Reply
RonIsWrong
RonIsWrong Oct. 1 at 1:42 PM
$JANX alright, looking better
0 · Reply
CooperHandy
CooperHandy Sep. 30 at 2:35 PM
0 · Reply
SweepCastApp
SweepCastApp Sep. 26 at 4:47 PM
$JANX: TRADE PUT trade alert 21 @ 12.10, Strike 35.0, Exp 11/21/2025, Premium $25,410, Sentiment BEARISH
0 · Reply
CH_Expat
CH_Expat Sep. 26 at 5:52 AM
$JANX Basically cash level. Even if the weird rumors are true, there is a lot of value in it. I keep watching.
3 · Reply
CH_Expat
CH_Expat Sep. 22 at 10:10 AM
$JANX For transparency, I sold. The weird rumour about 007 plus Robinson leaving plus the technicals are concerning me a bit.
2 · Reply
RonIsWrong
RonIsWrong Sep. 19 at 9:42 PM
$JANX termination without cause
2 · Reply
Houseofsweeps
Houseofsweeps Sep. 19 at 3:20 AM
$JANX stock has to make a move here soon. Let’s see what happens.
0 · Reply
termite
termite Sep. 17 at 11:17 PM
$JANX 007 trial now has 1 death and 3 trial participants with vision issues. Hard pass for me.
JarvisFlow
JarvisFlow Sep. 17 at 11:00 AM
Barclays updates rating for Janux Therapeutics ( $JANX ) to Overweight, target set at 47.
0 · Reply
Quantumup
Quantumup Sep. 16 at 9:06 PM
Barclays initiated coverage on $JANX at an Overweight rating and $47 and said, Janux has shown highly encouraging clinical data in late-line metastatic castration-resistant prostate cancer (mCRPC), with Progression-Free Survival (PFS) and Prostate Specific Antigen (PSA) reduction responses outperforming other late-line mCRPC options and competitive with standard of care options in earlier treatment settings. Given the performance of JANX007 to date, we view the earlier line treatment of prostate cancer with JANX007 as a logical move given its clinical efficacy to date and the economics associated with a large indication like prostate cancer. $NVS $AMGN $JNJ $AZN
1 · Reply
CH_Expat
CH_Expat Sep. 16 at 4:13 PM
$TRML 500 watchers, last post in May = bought out by Novartis. Retail knows shit in bio. I am happy with my positions in $IDYA and $JANX.
2 · Reply
CH_Expat
CH_Expat Sep. 12 at 5:28 PM
$JANX Finally opened a position here. 1100 for 24.40 USD. EV 400m is grossly undervalued, no matter how you look at it.
1 · Reply
Optionking828
Optionking828 Sep. 11 at 3:24 PM
$JANX same 3 year target and Janux has proved it continue to fail on ever aspect
0 · Reply
Theflash88
Theflash88 Sep. 10 at 7:17 PM
$JANX This: Truist Securities launched its coverage of Janux Therapeutics (NASDAQ:JANX) with a Buy recommendation and a $100 target on Wednesday, citing a catalyst-rich period for the cancer drug developer during the second half of the year.
0 · Reply
RonIsWrong
RonIsWrong Sep. 10 at 4:54 PM
$JANX ok, let's see.
1 · Reply
Quantumup
Quantumup Sep. 10 at 1:24 PM
Truist🏁 $JANX Buy/$100: Truist said: We initiate coverage of Janux Therapeutics ( $JANX ) with a Buy rating and $100 PT. [ $NVS $AMGN $JNJ $AZN ] Truist added: We believe the company's proprietary platforms (TRACTr and TRACIr) have the potential to overcome historical limitations of T-cell engagers in solid tumors by improving safety and efficacy through tumor-activated masking. Lead asset JANX007 has best-in-class potential in prostate cancer, and with multiple readouts across 2025, we see a catalyst rich year ahead. Where many peers have stumbled, Janux's masking technology offers a differentiated path to both efficacy and safety. With key data updates expected in the back half of 2025, we anticipate meaningful upside for investors.
0 · Reply
JarvisFlow
JarvisFlow Sep. 10 at 1:15 PM
Truist Securities has updated their rating for Janux Therapeutics ( $JANX ) to Buy with a price target of 100.
0 · Reply